Related Experiment Video

Updated: Jul 10, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy

Elizabeth Ruth Plummer1, Hilary Calvert

  • 1Northern Institute for Cancer Research, Newcastle University, United Kingdom. e.r.plummer@ncl.ac.uk

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 3, 2007
PubMed

Insights

DNA repair pathways protect the genome but can drive cancer and drug resistance. Poly(ADP-ribose) polymerase inhibitors target these pathways, with clinical strategies focusing on single- and double-strand break repair interactions.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • DNA repair pathways are crucial for maintaining genomic stability in normal cells.
  • In cancer cells, altered DNA repair can contribute to tumorigenesis and resistance to chemotherapy.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors are a class of drugs targeting DNA repair.

Purpose of the Study:

  • To discuss the interactions between single-strand break (SSB) and double-strand break (DSB) repair pathways.
  • To explain the rationale behind current clinical development strategies for PARP inhibitors.

Main Methods:

  • Review of existing literature on DNA repair mechanisms.
  • Analysis of the interplay between SSB and DSB repair pathways.
  • Discussion of clinical trial data and therapeutic strategies involving PARP inhibitors.

Main Results:

  • Disruption of DNA repair pathways can lead to cancer initiation.
  • Active DNA repair mechanisms in cancer cells can confer resistance to anticancer agents.
  • PARP inhibitors block SSB repair, creating synthetic lethality in cancers with defective DSB repair.

Conclusions:

  • Understanding the crosstalk between SSB and DSB repair is critical for effective cancer therapy.
  • PARP inhibitors represent a targeted approach to cancer treatment by exploiting DNA repair deficiencies.
  • Two main clinical strategies for PARP inhibitors are based on their interaction with DNA repair pathways.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...